Ranging from the Ft. Detrick MCM community to Glaxo and has authored World Health Organization reports, particularly on dengue. Vical gave notice in April of a clinical trial of a tetravalent Dengue vaccine trial with Vaxfectin adjuvant levels. i would go out the L2RD with him in a critical infectious disease investigation anytime. And he knows how GSK develops and promotes their vaccines.
Have colleagues who work with an organization who works with Ft. Detrick MCM. Lots of programs run by the DoD and other agencies came under Col. Mammen. He is by far one of the top experts in the world on HEP, Dengue, HIV, etc. This man knows is stuff. Vical is lucky to get him. Brings many connections to the government and PHARMA as stated earlier. Things will be bright for Vical, might take a little longer than folks want, but the company will be a shinning example of science and business in 2013.
If the Dengue fever vaccine is approved and sold to the military, what is VICL worth sans A-7? I'm just saying this because it would represent one of the smallest markets for their products, on the left hand part of the curve so to speak. The BMY agreement boosts confidence in the technology as does Mammen coming on board, he is not an oncologist so it is likely that he was attracted by the potential for the infectious disease vaccine arm of the company.